

Brain, immune system and selenium: a starting point for a new diagnostic marker for Alzheimer's disease?

Cesare Achilli; Annarita Ciana; Giampaolo Minetti

Laboratories of Biochemistry, Department of Biology and Biotechnology, University of Pavia, via Agostino Bassi, 21, Pavia, Italy

Corresponding author: Giampaolo Minetti; tel.: +39-0382-987891; fax: +39-0382-987240; e-mail: minetti@unipv.it

Keywords: Alzheimer's disease, neutrophil, selenium, methionine sulfoxide reductase

Highlights

MsrB1 is one of the 25 selenoenzymes expressed in the humans

MsrB1 is highly expressed in human circulating neutrophils

The diagnostic markers for Alzheimer's disease are still insufficiently validated

The impairment of some selenoenzymes is associated with Alzheimer's disease

Neutrophil MsrB1 can be a peripheral marker for the diagnosis of Alzheimer's disease

Abstract

The clinical diagnosis of Alzheimer's disease (AD) is based primarily on neuropsychological tests, which assess the involutive damage, and imaging techniques that evaluate morphologic changes in the brain. The currently available diagnostic tests do not show complete specificity and do not permit an accurate differentiation between AD and other forms of senile dementia. The correlation of these tests with laboratory investigations based on biochemical parameters could increase the certainty of the diagnosis. In recent years, several biochemical markers for the diagnosis of AD have been proposed, but in most cases they show a limited specificity and their application is invasive, because it generally requires the sampling of cerebrospinal fluid. Therefore, the use of a peripheral biochemical marker could represent a valuable complement for the diagnosis of this disease.

Several studies have shown a relationship between the neurodegenerative disorders typical of the ageing process, the weakening of the immune system, alterations in the levels of selenium and of the antioxidant selenoenzymes in brain tissues and blood cells, particularly in neutrophil granulocytes. The levels of peripheral selenoenzymes may reveal a promising clinical parameter for helping in the assessment of the pathological condition in AD.

Background

Selenium is an essential element involved in several cellular processes such as immune response, signal transduction, metabolism of thyroid hormones and defence against oxidative damage [1]. Selenium is contained in proteins as selenocysteine, which can be considered as the 21st proteinogenic amino acid. When selenocysteine is present in the active site of the protein, it confers to the enzyme a higher catalytic efficiency compared to cysteine. The most recent studies have revealed that 25 selenoproteins are expressed in humans [2, 3]. Many of them, such as glutathione peroxidase (GPx) and methionine sulfoxide reductase B1 (MsrB1), are oxidoreductase enzymes that contain selenocysteine in the catalytic site and are involved in the regulation of cellular redox processes [4].

Members of the GPx family perform the detoxification of reactive oxygen species (ROS) produced during the aerobic metabolism, through the reduction of organic peroxides using glutathione as the electron donor, and are characterised by different substrate specificity, cellular localization and tissue distribution [5].

During ageing, and in association with neurodegenerative diseases such as Alzheimer's disease (AD), a significant decrease of GPx activity in whole blood [6], erythrocytes [7-12], neutrophils [7, 13] and plasma [7, 14, 15] was observed. Quite remarkably neutrophils from patients affected by neurodegenerative diseases displayed less than 30% of the GPx activity of neutrophils from healthy individuals [7]. This phenomenon was correlated with the decrease in selenium levels that was observed to occur in plasma [7, 16, 17, 9, 18] and in erythrocytes [7, 18] during ageing and in individuals affected by various neurodegenerative disorders. In a sample of geriatric population, a 25% decrease in selenium plasma levels was observed, along with a 20% decrease in erythrocyte GPx activity [19]. The changes in selenium status that occur during ageing, which can be attributed to defects of assimilation and/or metabolism of this element, may lead to an increased susceptibility to various degenerative diseases typical of the elderly, including AD, which is characterised by

oxidative damage to various cellular components [20]. The increased oxidative stress associated with selenium deficiency has been correlated with defects in the regulation of GPx expression [21]. Low selenium levels increase significantly the risk of mortality during senility [22]. This element is therefore considered as an important factor for maintaining a good state of health in the elderly [23]. Components of both the innate and acquired immune systems deteriorate gradually during ageing [24, 25], and this functional impairment further aggravates in the course of AD [26, 27]. The cellular components that guarantee the efficiency of the innate immune response are the phagocytes: macrophages and neutrophil granulocytes, whose task is to engulf the pathogen into a phagosome and degrade it by means of proteolytic enzymes and various ROS, like superoxide, hydrogen peroxide and hypochlorite, produced during the so-called oxidative burst. As ROS can diffuse from the phagosome into the cytosol during the burst, and thus compromise cell function, neutrophils are endowed with powerful antioxidant systems, both enzymatic and non-enzymatic, that act to prevent or repair the oxidative damage [28]. Selenium is essential for the full efficiency of various components of the immune system, both acquired and innate [29, 30]. Several studies conducted in mice and humans have shown that selenium deficiency, as indicated by the loss of GPx activity, leads to a reduction in the phagocytic capacity and in the intensity of the oxidative burst in neutrophils, resulting in decreased bactericidal activity [31, 32], whereas selenium supplementation in the diet restores GPx activity and cell function [32].

Studies in vitro with HL-60 cells (a human promyelocytic leukaemia cell line that can be induced to differentiate into a neutrophilic phenotype) grown in a selenium-deficient medium indicate the complete absence of GPx, whose expression is restored to values comparable to those measured in neutrophils when the medium is supplemented with appropriate amounts of selenium [33, 34]. Another study indicate that the supplementation of selenium in the diet of humans with selenium deficiency associated with neurodegenerative diseases increases both selenium levels and GPx

activity in plasma and erythrocytes [7]. These data indicate that GPx expression is very sensitive to the levels of selenium in the organism.

The decrease in neutrophil's bactericidal capacity appears to be linked to ROS accumulation and to correlate with the loss of GPx activity, resulting in a redox imbalance in the cells, which become therefore more sensitive to oxidative damages. Neutrophils from AD patients were found to contain high concentrations of intracellular ROS under resting conditions, pointing to a defect in antioxidant systems of these cells [35].

Human neutrophils are the cell type with the highest selenium concentration, although it has been shown that the levels of GPx activity are lower than those measured in other cell types, such as in kidney and liver. Moreover, neutrophils of mice subjected to a diet supplemented with selenite display, at low selenium concentrations, an increase in bactericidal activity but not in GPx activity, while only at higher concentrations of selenium the two activities increase in parallel [32]. These data suggest that the expression of GPx is particularly dependent on the selenium status of the organism, and, most importantly, that this protein is not the only selenoenzyme that ensures proper neutrophil function.

Only one other selenoenzyme with anti-oxidant function has been characterised in detail in human neutrophils [36]. It is MsrB1, belonging to the family of methionine sulfoxide reductases (MsrA and MsrB), and the only form of Msr containing a catalytically active selenocysteine [37]. The Msrs catalyse the stereospecific reduction of the two diastereoisomers of methionine sulfoxide, which are generated by the oxidation of the sulphide group of methionine, as the free amino acid or when it is present in proteins: [Msrs reduce (S_C)methionine-(S_S)sulfoxide, while MsrBs reduce (S_C)methionine-(R_S)sulfoxide] [38]. Msrs perform three main tasks: (i) the repair of the oxidative damage suffered by methionine residues, which results in the alteration of function of many proteins, such as the beta-amyloid peptide, in which the oxidation of methionine appears critical for aggregation, neurotoxicity, and the generation of ROS induced by the peptide [39]; (ii) the

detoxification of ROS through the cyclic oxidation/reduction of methionine, free or inserted in some proteins, thus preventing the oxidation of other particularly sensitive cellular components [40]; (iii) the regulation of cellular metabolism through changes in the redox state of specific methionine residues present in various enzymes, hormones and plasma proteins [41]. The imbalance in the methionine/methionine sulfoxide ratio can alter the metabolic functions, contributing to the development of diseases related to the impairment of the cellular processes affected [42].

The selenoenzyme MsrB1 is the form predominantly expressed in circulating human neutrophils, but is almost entirely absent in other blood cells [36]. MsrB1, like GPx, would be a component of the selenium-dependent antioxidant machinery that has evolved in neutrophils to counteract the ROS produced in high concentrations during the immune response.

Hypothesis

We propose this hypothesis: the selenoenzyme MsrB1 from neutrophil granulocytes could represent a more specific indicator of the selenium status in the organism and in particular a new peripheral diagnostic marker for AD, alternative to, or in combination with those proposed, which are typically invasive since they involve the analysis of cerebrospinal fluid, and display low specificity [43, 44].

Results and Discussion

Concerning the hypothesis presented here, MsrB1 activity was analysed in neutrophil samples from healthy donors and patients affected by AD associated with diversified diseases typical of the elderly. A limited cohort of patients was studied, not allowing statistical elaboration, therefore the present study should be considered as a preliminary investigation. Yet, this pilot study showed that the patients could be grouped in two populations: one group with MsrB1 specific activity similar to that of healthy donors, and one group with approximately the 50% of the specific activity of healthy donors (Figure 1).




Figure 1. Specific activity of MsrB1 (pmol of dabsyl-methionine produced per min per mg total protein) detected in neutrophils from: healthy donors (n=8), "normal MsrB1 activity" patients (n=8), and "low MsrB1 activity" patients (n=5).

The novel finding of decreased MsrB1 activity with ageing presented here is consistent with literature data about the decrease in antioxidant defence, and particularly of selenoenzymes, associated with age-related neurodegenerative pathologies typical of the elderly. Moreover, particularly remarkable is a post-mortem observation that showed a significant decrease in Msr activity (MsrA plus MsrB) in various areas of the brain in subjects affected by AD [45]. The alterations observed in the immune system of patients suffering from neurodegenerative disorders, particularly AD, suggest a correlation between the two events, supporting the hypothesis of a systemic nature of this disease [26, 46]. The observation of a concomitant impairment of Msr activity in brain tissues and peripheral neutrophils, in association with AD, seem to corroborate this hypothesis.

Moreover, the increase in the intracellular content of oxidized proteins, especially at the level of methionine residues, which occurs during ageing, has been correlated with the onset of degenerative diseases typical of advanced age [42, 47, 48]. The limited capacity of reduction of methionine sulfoxide by Msr enzymes, including the selenoenzyme MsrB1, renders the defence systems against oxidative stress inadequate, thus favouring the onset of degenerative diseases, like the Alzheimer's, which are characterised by accumulation of oxidized proteins [42, 47].

In light of the preliminary evidence presented here, the idea of a correlation between AD, partial impairment of the immune system and decreased MsrB1 activity should be further investigated. It is also to be clarified whether the decline MsrB1 activity observed in some AD patients was due to a decrease in protein expression or to an impairment of the catalytic activity. Although MsrB1 was discovered in 1999 [38], it is still poorly studied and it has not yet been considered as a possible indicator of the selenium status of the organism [49]. Therefore, we deem it of particular interest to explore the potential use of MsrB1 as a selective and reliable diagnostic, peripheral marker for AD, a very invalidating neurodegenerative condition that afflicts millions of people in the world, and for which none of the imaging or neurochemical diagnostic markers proposed to date can be considered to be sufficiently validated [50].

Methods

Purification of human neutrophils

Fresh human blood was from the Institute of Geriatric Rehabilitation “Santa Margherita” (Pavia, Italy) and from the Immunohematology and Transfusion Medicine Department of the “San Matteo” Hospital (Pavia, Italy) as approved by the respective internal Institution Review Boards. Neutrophils were obtained by Dextran-70 sedimentation of blood followed by Ficoll-Hypaque gradient centrifugation, essentially as described [51] with minor modifications [52], washed in PBS supplemented with 2 mM EDTA and 0.5% (w/v) BSA, and centrifuged at 500g for 10 min at 4 °C.

The residual erythrocytes in the neutrophils-rich fraction were eliminated by differential hypotonic lysis with ice cold 0.2% (w/v) NaCl for 30 s under agitation. The isotonicity was restored by adding an equal volume of 1.6% (w/v) NaCl. The cells were sedimented under the same conditions, and then washed three times in supplemented PBS. The number of neutrophils was determined by microscope-count, and the samples were then stored frozen at -80°C .

Determination of methionine sulfoxide reductase activity

Purified neutrophils were resuspended (10^8 cells/ml) in PBS containing 1% (v/v) Triton X-100 and 0.1% (v/v) diisopropylfluorophosphate as a serine-protease inhibitor, and left on ice for 30 min. The lysate was then centrifuged at 18000 g for 10 min at 4°C . The supernatant was collected and analyzed directly. Protein concentration was assayed with the bicinchoninic acid method using BSA as a standard.

MsrB enzymatic activity was assayed using the *R* diastereoisomer of methionine sulfoxide conjugated with the dabsyl group as the substrate, and 1,4-dithioerythritol as the electron donor. Methionine-*R*-sulfoxide was separated from its optical antipode as described [53, 54] and functionalized with the dabsyl group as described [55]. The reaction mixture contained 5 mM sodium phosphate (pH 7.4), 154.5 mM NaCl, 4.5 mM KCl, 20 mM 1,4-dithioerythritol, 500 μM dabsyl-methionine-*R*-sulfoxide and 50 μg of total protein from the cell extract. The reaction was carried out at 37°C for 30 min, and the reaction product, dabsyl-methionine, was analyzed by reverse-phase HPLC, monitoring the chromophoric dabsyl moiety at the wavelength of 436 nm [55].

Acknowledgments

This work was supported by the University of Pavia, FAR funds to GM.

References

- 1) Rayman MP. The importance of selenium to human health. *Lancet* 2000;356:233-241.
- 2) Kryukov GV, Castellano S, Novoselov SV, Lobanov AV, Zehtab O, Guigò R, Gladyshev VN. Characterization of Mammalian Selenoproteomes. *Science* 2003;300:1439-1443.
- 3) Papp LV, Lu J, Holmgren A, Khanna KK. From selenium to selenoproteins: synthesis, identity, and their role in human health. *Antioxid Redox Signal* 2007;9:775-806.
- 4) Hawkes WC, Alkan Z. Regulation of redox signaling by selenoproteins. *Biol Trace Elem Res* 2010;134:235-251.
- 5) Schweizer U, Bräuer AU, Köhrle J, Nitsch R, Savaskan NE. Selenium and brain function: a poorly recognized liaison. *Brain Res Brain Res Rev* 2004;45:164-178.
- 6) Espinoza SE, Guo H, Fedarko N, DeZern A, Fried LP, Xue QL, Leng S, Beamer B, Walston JD. Glutathione peroxidase enzyme activity in aging. *J Gerontol A Biol Sci Med Sci* 2008;63:505-509.
- 7) Clausen J, Jensen GE, Nielsen SA. Selenium in chronic neurologic diseases. Multiple sclerosis and Batten's disease. *Biol Trace Elem Res* 1988;15:179-203.
- 8) Kharrazi H, Vaisi-Raygani A, Rahimi Z, Tavilani H, Aminian M, Pourmotabbed T. Association between enzymatic and non-enzymatic antioxidant defense mechanism with apolipoprotein E genotypes in Alzheimer disease. *Clin Biochem* 2008;41:932-936.
- 9) Demirin H, Kara Y, Eren I, Delibas N. Alterations of plasma magnesium, copper, zinc, iron and selenium concentrations and some related erythrocyte antioxidant enzyme activities in patients with Alzheimer's disease. *J Trace Elem Med Biol* 2010;24:169-173.
- 10) Jeandel C, Nicolas MB, Dubois F, Nabet-Belleville F, Penin F, Cuny G. Lipid peroxidation and free radical scavengers in Alzheimer's disease. *Gerontology* 1989;35:275-282.
- 11) Johannsen P, Velander G, Mai J, Thorling EB, Dupont E. Glutathione peroxidase in early and advanced Parkinson's disease. *J Neurol Neurosurg Psychiatry* 1991;54:679-682.
- 12) Syburra C, Passi S. Oxidative stress in patients with multiple sclerosis. *Ukr Biokhim Zh* 1999;71:112-115.
- 13) Ito Y, Kajkenova O, Feuers RJ, Udupa KB, Desai VG, Epstein J, Hart RW, Lipschitz DA. Impaired glutathione peroxidase activity accounts for the age-related accumulation of hydrogen peroxide in activated human neutrophils. *J Gerontol A Biol Sci Med Sci* 1998;53:169-175.
- 14) Rinaldi P, Polidori MC, Metastasio A, Mariani E, Mattioli P, Cherubini A, Catani M, Cecchetti R, Senin U, Mecocci P. Plasma antioxidants are similarly depleted in mild cognitive impairment and in Alzheimer's disease. *Neurobiol Aging* 2003;24:915-919.
- 15) Padurariu M, Ciobica A, Hritcu L, Stoica B, Bild W, Stefanescu C. Changes of some oxidative stress markers in the serum of patients with mild cognitive impairment and Alzheimer's disease. *Neurosci Lett* 2010;469:6-10.
- 16) Smorgon C, Mari E, Atti AR, Dalla Nora E, Zamboni PF, Calzoni F, Passaro A, Fellin R. Trace elements and cognitive impairment: an elderly cohort study. *Arch Gerontol Geriatr* 2004;Suppl. 9:393-402.
- 17) Akbaraly TN, Hininger-Favier I, Carrière I, Arnaud J, Gourlet V, Roussel AM, Berr C. Plasma selenium over time and cognitive decline in the elderly. *Epidemiology* 2007;18:52-58.

- 18) Cardoso BR, Ong TP, Jacob-Filho W, Jaluul O, Freitas MI, Cozzolino SM. Nutritional status of selenium in Alzheimer's disease patients. *Br J Nutr* 2010;103:803-806.
- 19) Olivieri O, Stanzial AM, Girelli D, Trevisan MT, Guarini P, Terzi M, Caffi S, Fontana F, Casaril M, Ferrari S, Corrocher R. Selenium status, fatty acids, vitamins A and E, and aging: the Nove Study. *Am J Clin Nutr* 1994;60:510-517.
- 20) Stadtman ER, Berlett BS. Reactive oxygen-mediated protein oxidation in aging and disease. *Chem Res Toxicol* 1997;10:485-494.
- 21) Lei XG, Cheng WH, McClung JP. Metabolic regulation and function of glutathione peroxidase-1. *Annu Rev Nutr* 2007;27:41-61.
- 22) Walston J, Xue Q, Semba RD, Ferrucci L, Cappola AR, Ricks M, Guralnik J, Fried LP. Serum antioxidants, inflammation, and total mortality in older women. *Am J Epidemiol* 2006;163:18-26.
- 23) González S, Huerta JM, Fernández S, Patterson AM, Lasheras C. Life-quality indicators in elderly people are influenced by selenium status. *Aging Clin Exp Res* 2007;19:10-15.
- 24) Gomez CR, Nomellini V, Faunce DE, Kovacs EJ. Innate immunity and aging. *Exp Gerontol* 2008;43:718-728.
- 25) Fulop T, Larbi A, Douziech N, Fortin C, Guérard KP, Lesur O, Khalil A, Dupuis G. Signal transduction and functional changes in neutrophils with aging. *Aging Cell* 2004;3:217-226.
- 26) Shalit F, Sredni B, Brodie C, Kott E, Huberman M. T lymphocyte subpopulations and activation markers correlate with severity of Alzheimer's disease. *Clin Immunol Immunopathol* 1995;75:246-250.
- 27) Song C, Vandewoude M, Stevens W, De Clerck L, Van der Planken M, Whelan A, Anisman H, Dossche A, Maes M. Alterations in immune functions during normal aging and Alzheimer's disease. *Psychiatry Res* 1999;85:71-80.
- 28) Splettstoesser WD, Schuff-Werner P. Oxidative stress in phagocytes - "the enemy within". *Microsc Res Tech* 2002;57:441-455.
- 29) Hoffmann PR. Mechanisms by which selenium influences immune responses. *Arch Immunol Ther Exp (Warsz)* 2007;55:289-297.
- 30) Hoffmann PR, Berry MJ. The influence of selenium on immune responses. *Mol Nutr Food Res* 2008;52:1273-1280.
- 31) Serfass RE, Ganther HE. Defective microbicidal activity in glutathione peroxidase-deficient neutrophils of selenium-deficient rats. *Nature* 1975;255:640-641.
- 32) Arthur JR, McKenzie RC, Beckett GJ. Selenium in the immune system. *J Nutr* 2003;133:1457-1459.
- 33) Takahashi K, Newburger PE, Cohen HJ. Glutathione peroxidase protein. Absence in selenium deficiency states and correlation with enzymatic activity. *J Clin Invest* 1986;77:1402-1404.
- 34) Chada S, Whitney C, Newburger PE. Post-transcriptional regulation of glutathione peroxidase gene expression by selenium in the HL-60 human myeloid cell line. *Blood* 1989;74:2535-2541.
- 35) Vitte J, Michel BF, Bongrand P, Gastaut JL. Oxidative stress level in circulating neutrophils is linked to neurodegenerative diseases. *J Clin Immunol* 2004;24:683-692.
- 36) Achilli C, Ciana A, Rossi A, Balduini C, Minetti G. Neutrophil granulocytes uniquely express, among human blood cells, high levels of Methionine-sulfoxide-reductase enzymes. *J Leukoc Biol* 2008;83:181-189.

- 37) Kim HY, Gladyshev VN. Methionine sulfoxide reductases: selenoprotein forms and roles in antioxidant protein repair in mammals. *Biochem J* 2007;407:321-329.
- 38) Achilli C, Ciana A, Minetti G. The discovery of methionine sulfoxide reductase enzymes: An historical account and future perspectives. *Biofactors* 2015;41:135-152.
- 39) Varadarajan S, Kanski J, Aksenova M, Lauderback C, Butterfield DA. Different mechanisms of oxidative stress and neurotoxicity for Alzheimer's A beta(1-42) and A beta(25-35). *J Am Chem Soc* 2001;123:5625-5631.
- 40) Weissbach H, Resnick L, Brot N. Methionine sulfoxide reductases: history and cellular role in protecting against oxidative damage. *Biochim Biophys Acta* 2005;1703:203-212.
- 41) Hansel A, Heinemann SH, Hoshi T. Heterogeneity and function of mammalian MSRs: enzymes for repair, protection and regulation. *Biochim Biophys Acta* 2005;1703:239-247.
- 42) Stadtman ER, Van Remmen H, Richardson A, Wehr NB, Levine RL. Methionine oxidation and aging. *Biochim Biophys Acta* 2005;1703:135-140.
- 43) Bailey P. Biological markers in Alzheimer's disease. *Can J Neurol Sci* 2007;34:72-76.
- 44) Galasko D, Montine TJ. Biomarkers of oxidative damage and inflammation in Alzheimer's disease. *Biomark Med* 2010;4:27-36.
- 45) Gabbita SP, Aksenov MY, Lovell MA, Markesbery WR. Decrease in peptide methionine sulfoxide reductase in Alzheimer's disease brain. *J Neurochem* 1999;73:1660-1666.
- 46) Fortin CF, McDonald PP, Lesur O, Fülöp T Jr. Aging and neutrophils: there is still much to do. *Rejuvenation Res* 2008;11:873-882.
- 47) Stadtman ER. Protein oxidation and aging. *Free Radic Res* 2006;40:1250-1258.
- 48) Radak Z, Zhao Z, Goto S, Koltai E. Age-associated neurodegeneration and oxidative damage to lipids, proteins and DNA. *Mol Aspects Med* 2011;32:305-315.
- 49) Combs GF. Biomarkers of Selenium Status. *Nutrients* 2015;7:2209-2236.
- 50) Hampel H, Broich K, Hoessler Y, Pantel J. Biological markers for early detection and pharmacological treatment of Alzheimer's disease. *Dialogues Clin Neurosci* 2009;11:141-157.
- 51) Böyum A. Isolation of mononuclear cells and granulocytes from human blood. Isolation of mononuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g. *Scand J Clin Lab Invest (Suppl)* 1968;97: 77-89.
- 52) Melloni E, Pontremoli S, Michetti M, Sacco O, Sparatore B, Salamino F, Horecker BL. Binding of protein kinase C to neutrophil membranes in the presence of Ca²⁺ and its activation by a Ca²⁺-requiring proteinase. *Proc Natl Acad Sci U S A* 1985;82:6435-6439.
- 53) Lavine TF. The formation, resolution, and optical properties of the diastereoisomeric sulfoxides derived from L-methionine. *J Biol Chem* 1947;169:477-491.
- 54) Greenstein JP, Winitz M. *Chemistry of the Amino Acids*, Krieger Publishing Company, Malabar, vol. 3, 2125-2155 (1984).
- 55) Minetti G, Balduini C, Brovelli A. Reduction of DABS-L-methionine-dl-sulfoxide by protein methionine sulfoxide reductase from polymorphonuclear leukocytes: stereospecificity towards the l-sulfoxide. *Ital J Biochem* 1994;43:273-283.